BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 425 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 425 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $25.46, for a total value of $10,820.50. Following the transaction, the executive vice president now directly owns 262,198 shares in the company, valued at approximately $6,675,561.08. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

BioLife Solutions Stock Up 5.7 %

BLFS stock opened at $26.25 on Thursday. The firm has a 50-day moving average of $26.67 and a two-hundred day moving average of $25.48. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the firm earned ($0.21) EPS. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC boosted its position in BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the period. The Manufacturers Life Insurance Company boosted its position in BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after buying an additional 5,638 shares during the period. Barclays PLC boosted its position in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the period. Finally, D.A. Davidson & CO. purchased a new position in BioLife Solutions in the 3rd quarter valued at approximately $1,018,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, Craig Hallum increased their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.